Screener
AtriCure ATRC D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by AtriCure in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: AtriCure’s 10-Q, filed July 27, 2026.
- Filed
- Jul 27, 2026, 1:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001323885-26-000035
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net income (loss) | $9,063 | $(12,937) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Share-based compensation expense | 23,586 | 21,001 |
| Depreciation | 5,812 | 6,034 |
| Amortization of intangible assets | 4,768 | 4,221 |
| Amortization of deferred financing costs | 210 | 239 |
| Acquired in-process research and development expense | — | 5,000 |
| Other non-cash adjustments | 1,177 | 311 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is AtriCure's D&A?
- AtriCure (ATRC) reported D&A of $2.92M in Q2 2026.
- How has AtriCure's D&A changed year-over-year?
- AtriCure's D&A decreased by 4.5% year-over-year, from $3.06M to $2.92M.
- What is the long-term trend for AtriCure's D&A?
- Over 4 years (2021 to 2025), AtriCure's D&A has grown at a 12.6% compound annual growth rate (CAGR), from $7.53M to $12.09M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about AtriCure's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude